Patents by Inventor M. Zouhair Atassi

M. Zouhair Atassi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
    Publication number: 20130330369
    Abstract: The present invention provides a method of tolerizing a subject to botulinum toxin and botulinum toxin variants.
    Type: Application
    Filed: October 7, 2011
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: M. Zouhair Atassi, Behzod Z. Dolimbek, K. Roger Aoki
  • Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin A peptides
    Patent number: 8236513
    Abstract: The present invention provides BoNT/A peptide compositions, tolerogizing compositions, BoNT/A immune response inducing compositions and antibody compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of preventing or reducing immunoresistance to botulinum toxin therapy in an individual, methods of vaccinating an individual against botulinum toxin, methods of preparing anti-BoNT/A antibodies, methods of treating botulinum toxicity in an individual and methods of reducing anti-botulinum toxin antibodies in an individual.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: August 7, 2012
    Assignee: Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Bont/a peptides and methodsof predicting and reducing immunoresistance to botulinum toxin therapy
    Patent number: 8137675
    Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: March 20, 2012
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Determining and reducing immunoresistance to a toxin therapy using toxin B peptides
    Patent number: 7972801
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: July 5, 2011
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin B peptides
    Patent number: 7968304
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: June 28, 2011
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Tolerogizing compositions comprising botulinum toxin type B peptides
    Patent number: 7855268
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: December 21, 2010
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • BoNT/A Peptides and Methods of Predicting and Reducing Immunoresistance to Botulinum Toxin Therapy
    Publication number: 20100284958
    Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
    Type: Application
    Filed: October 30, 2009
    Publication date: November 11, 2010
    Inventor: M. Zouhair Atassi
  • BoNT/A PEPTIDES AND METHODSOF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY
    Publication number: 20100278856
    Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
    Type: Application
    Filed: October 29, 2009
    Publication date: November 4, 2010
    Inventor: M. Zouhair Atassi
  • Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides
    Publication number: 20100112609
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Application
    Filed: January 6, 2010
    Publication date: May 6, 2010
    Inventor: M. ZOUHAIR ATASSI
  • Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides
    Publication number: 20100111962
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Application
    Filed: January 7, 2010
    Publication date: May 6, 2010
    Inventor: M. Zouhair Atassi
  • Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides
    Publication number: 20100112082
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Application
    Filed: January 6, 2010
    Publication date: May 6, 2010
    Inventor: M. Zouhair Atassi
  • Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides
    Publication number: 20100112610
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Application
    Filed: January 6, 2010
    Publication date: May 6, 2010
    Inventor: M. ZOUHAIR ATASSI
  • Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin B peptides
    Patent number: 7691587
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: April 6, 2010
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Determining and reducing immunoresistance to a Botulinum toxin therapy using Botulinum toxin B peptides
    Patent number: 7670788
    Abstract: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: March 2, 2010
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
    Patent number: 7635484
    Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: December 22, 2009
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Molecular-specific urokinase antibodies
    Patent number: 7541159
    Abstract: Antibodies have been developed against the different molecular forms of urokinase using synthetic peptides as immunogens. The peptides were synthesized specifically to represent those regions of the urokinase molecules which are exposed in the three-dimensional configuration of the molecule and are uniquely homologous to urokinase. Antibodies are directed against the lysine 158-isoleucine 159 peptide bond which is cleaved during activation from the single-chain (ScuPA) form to the bioactive double chain (54 KDa and 33 KDa) forms of urokinase and against the lysine 135 lysine 136 bond that is cleaved in the process of removing the alpha-chain from the 54 KDa form to produce the 33 KDa form of urokinase. These antibodies enable the direct measurement of the different molecular forms of urokinase from small samples of conditioned medium harvested from cell cultures.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: June 2, 2009
    Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
    Inventors: M. Zouhair Atassi, Dennis R. Morrison
  • BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
    Patent number: 7531179
    Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: May 12, 2009
    Assignee: Allergan, Inc.
    Inventor: M. Zouhair Atassi
  • DETERMINING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY USING BOTULINUM TOXIN A PEPTIDES
    Publication number: 20090004680
    Abstract: The present invention provides BoNT/A peptide compositions, tolerogizing compositions, BoNT/A immune response inducing compositions and antibody compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of preventing or reducing immunoresistance to botulinum toxin therapy in an individual, methods of vaccinating an individual against botulinum toxin, methods of preparing anti-BoNT/A antibodies, methods of treating botulinum toxicity in an individual and methods of reducing anti-botulinum toxin antibodies in an individual.
    Type: Application
    Filed: August 15, 2008
    Publication date: January 1, 2009
    Inventor: M. Zouhair Atassi
  • BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
    Patent number: 7462699
    Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: December 9, 2008
    Assignees: Allergan, Inc., Baylor College of Medicine
    Inventor: M. Zouhair Atassi
  • Botulinum Toxin Type a Immunoresistant Assay
    Publication number: 20080274480
    Abstract: The present specification discloses methods for determining Botulinum Toxin Type A immunoresistance in a mammal by detecting the amount of BoNT/A toxin-BoNT/A receptor complexes or the amount of free BoNT/A present or absent in a sample.
    Type: Application
    Filed: August 2, 2005
    Publication date: November 6, 2008
    Applicant: ALLERGAN, INC.
    Inventor: M. Zouhair Atassi